Various insulin regimens are used to treat patients with type 2 diabetes mellitus that ... the efficacy and safety of adding biphasic, prandial or basal insulin to oral therapy for these patients.

Conclusion: In clinical trials of patients with type 2 diabetes mellitus, vildagliptin has been shown to reduce HbA 1c, fasting plasma glucose levels, prandial ... of inhaled insulin, none of ...

Noninferiority of URLi versus insulin lispro was shown in change of HbA1c from baseline to week 26. (b) LSM post-prandial glucose excursions at weeks 26 during mixed-meal tolerance tests.